Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using Antithymocyte Globulin With Either Melphalan and Cladribine or Total Lymphoid Irradiation

NCT01272817 is registered in ClinicalTrials.gov with Scripps Health as lead sponsor.

NCT NCT01272817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01272817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using Antithymocyte Globulin With Either Melphalan and Cladribine or Total Lymphoid Irradiation
Lead sponsor
Scripps Health
Phase
Not applicable
Overall status
Completed
Start date
October 31, 2001
Completion date
October 31, 2015
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia, acute myelogenous leukemia, aplastic anemia, breast cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, hodgkin's lymphoma, mantle cell lymphoma, melanoma, multiple myeloma, myelodysplastic syndrome, non-hodgkin's lymphoma, ovarian cancer, paroxysmal nocturnal hemoglobinuria, renal cell carcinoma, sarcoma, thymoma, waldenstrom macroglobulinemia